The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pro-survival Function of Akt/Protein Kinase B in Prostate Cancer Cells
Thakkar, H., Chen, X., Tyan, F., Gim, S., Robinson, H. M., Lee, C., Pandey, S., Nwokorie, C., Onwudiwe, N. C., & Srivastava, R. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103321200 · Cited by 108
RetractedChawla‐Sarkar, M., Bauer, J. A., Lupica, J. A., Morrison, B., Tang, Z., Oates, R. K., Almasan, A., DiDonato, J. A., Borden, E. C., & Lindner, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306111200 · Cited by 77
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Du, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000) · Cell · doi:10.1016/s0092-8674(00)00008-8 · Cited by 3,513
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Self-citationIdentification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Thus, activating Fc-receptor-mediated immune activation can be a great advantage of antibody-based therapy of tumour”
BackgroundInhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., & Vaux, D. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00009-x · Cited by 2,372
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Apoptosis control by death and decoy receptors
Ashkenazi, A., & Dixit, V. M. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80034-9 · Cited by 1,288
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis
Vince, J. E., Wong, W. W.-L., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.037 · Cited by 1,053
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829
Self-citationTeitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000) · Nature Medicine · doi:10.1038/75007 · Cited by 811
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775
Self-citationLife in the balance: how BH3-only proteins induce apoptosis
Willis, S. N., & Adams, J. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.10.001 · Cited by 743
Chaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., & Hood, L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80400-8 · Cited by 711
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF-κB
Schneider, P., Thome, M., Burns, K., Bodmer, J.-L., Hofmann, K., Kataoka, T., Holler, N., & Tschopp, J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80401-x · Cited by 696
A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death
Li, L., Thomas, R. M., Suzuki, H., De Brabander, J. K., Wang, X., & Harran, P. G. (2004) · Science · doi:10.1126/science.1098231 · Cited by 656
A novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 629
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619
Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616
Self-citationWagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612
IAPs, RINGs and ubiquitylation
Vaux, D. L., & Silke, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1621 · Cited by 610
Luo, J.-L., Maeda, S., Hsu, L.-C., Yagita, H., & Karin, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.012 · Cited by 603
Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced Apoptosis
Petersen, S. L., Wang, L., Yalcin-Chin, A., Li, L., Peyton, M., Minna, J., Harran, P., & Wang, X. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.029 · Cited by 571
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita, H., & Okumura, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.661 · Cited by 512
Self-citationKayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., & Yagita, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1451 · Cited by 479
Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL
Griffith, T. S., Wiley, S. R., Kubin, M. Z., Sedger, L. M., Maliszewski, C. R., & Fanger, N. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1343 · Cited by 476
Recruitment of TNF Receptor 1 to Lipid Rafts Is Essential for TNFα-Mediated NF-κB Activation
Legler, D. F., Micheau, O., Doucey, M.-A., Tschopp, J., & Bron, C. (2003) · Immunity · doi:10.1016/s1074-7613(03)00092-x · Cited by 466
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
Self-citationTRAIL signalling: Decisions between life and death
Falschlehner, C., Emmerich, C. H., Gerlach, B., & Walczak, H. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.007 · Cited by 458
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
Fulda, S., Meyer, E., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205258 · Cited by 394
Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. (2001) · International Immunology · doi:10.1093/intimm/13.4.459 · Cited by 379
Self-citationNK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J. (2008) · International Immunology · doi:10.1093/intimm/dxn028 · Cited by 377
Self-citationNature's TRAIL—On a Path to Cancer Immunotherapy
Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R. M., & Yagita, H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00502-2 · Cited by 366
Self-citationExpression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells
Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 340
Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening
Aza-Blanc, P., Cooper, C. L., Wagner, K., Batalov, S., Deveraux, Q. L., & Cooke, M. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00348-4 · Cited by 340
Fc receptors are required in passive and active immunity to melanoma
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.652 · Cited by 321
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
Ravi, R., Bedi, G. C., Engstrom, L. W., Zeng, Q., Mookerjee, B., Gélinas, C., Fuchs, E. J., & Bedi, A. (2001) · Nature Cell Biology · doi:10.1038/35070096 · Cited by 312
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 305
Secchiero, P., Gonelli, A., Carnevale, E., Milani, D., Pandolfi, A., Zella, D., & Zauli, G. (2003) · Circulation · doi:10.1161/01.cir.0000062702.60708.c4 · Cited by 304
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S. K., Nwokorie, C., Onwudiwe, N., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204736 · Cited by 298
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284
Hotte, S. J., Winquist, E. W., Lamont, E., MacKenzie, M., Vokes, E., Chen, E. X., Brown, S., Pond, G. R., Murgo, A., & Siu, L. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.125 · Cited by 278
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H., & Ungefroren, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203936 · Cited by 275
Ehrhardt, H., Fulda, S., Schmid, I., Hiscott, J., Debatin, K.-M., & Jeremias, I. (2003) · Oncogene · doi:10.1038/sj.onc.1206520 · Cited by 272
Eradication of established tumors in mice by a combination antibody-based therapy
Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F., Okumura, K., Yagita, H., & Smyth, M. J. (2006) · Nature Medicine · doi:10.1038/nm1405 · Cited by 257
Self-citationRicci, M. S., Kim, S.-H., Ogi, K., Plastaras, J. P., Ling, J., Wang, W., Jin, Z., Liu, Y. Y., Dicker, D. T., Chiao, P. J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.006 · Cited by 255
TRAIL and its receptors as targets for cancer therapy
Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M. J., & Okumura, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02181.x · Cited by 254
Self-citationRegulation of apoptosis proteins in cancer cells by ubiquitin
Zhang, H.-G., Wang, J., Yang, X., Hsu, H.-C., & Mountz, J. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207373 · Cited by 247
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247
Hopkins-Donaldson, S., Bodmer, J.-L., Bourloud, K. B., Brognara, C. B., Tschopp, J., & Gross, N. (2000) · PubMed · Cited by 245
Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity
Ricci, M. S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., Dicker, D. T., & El-Deiry, W. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8541-8555.2004 · Cited by 243
Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies
Griffith, T. S., Rauch, C. T., Smolak, P. J., Waugh, J. Y., Boiani, N., Lynch, D. H., Smith, C. A., Goodwin, R. G., & Kubin, M. Z. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2597 · Cited by 241
Wu, G. S., Burns, T. F., Zhan, Y.-A., Alnemri, E. S., & El‐Deiry, W. S. (1999) · PubMed · Cited by 238
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.27 · Cited by 235
Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., Screaton, G., Lenardo, M. J., & Chan, F. K.-M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507329102 · Cited by 232
Rosato, R. R., Almenara, J. A., Dai, Y., & Grant, S. (2003) · PubMed · Cited by 232
Shin, M. S., Kim, H. S., Lee, S. H., Park, W. S., Kim, S. Y., Park, J. Y., Lee, J. H., Lee, S., Lee, S. N., Jung, S. S., et al. (2001) · PubMed · Cited by 229
Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death
Muppidi, J. R., & Siegel, R. M. (2004) · Nature Immunology · doi:10.1038/ni1024 · Cited by 227
Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines
Harada, K., Toyooka, S., Maitra, A., Maruyama, R., Toyooka, K. O., Timmons, C. F., Tomlinson, G. E., Mastrangelo, D., Hay, R. J., Minna, J. D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205446 · Cited by 226
Gaither, A., Porter, D., Yao, Y., Borawski, J., Yang, G., Donovan, J., Sage, D., Slisz, J., Tran, M., Straub, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-5173 · Cited by 224
Ovcharenko, D., Kelnar, K., Johnson, C., Leng, N., & Brown, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1484 · Cited by 224
Hayakawa, Y., Screpanti, V., Yagita, H., Grandien, A., Ljunggren, H.-G., Smyth, M. J., & Chambers, B. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.123 · Cited by 223
Self-citationTRAIL-R as a Negative Regulator of Innate Immune Cell Responses
Diehl, G. E., Yue, H. H., Hsieh, K., Kuang, A. A., Ho, M., Morici, L. A., Lenz, L. L., Cado, D., Riley, L. W., & Winoto, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.11.008 · Cited by 212
The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer
Vucic, D., & Fairbrother, W. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0729 · Cited by 206
Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
Takeda, K., Yamaguchi, N., Akiba, H., Kojima, Y., Hayakawa, Y., Tanner, J. E., Sayers, T. J., Seki, N., Okumura, K., Yagita, H., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031457 · Cited by 206
Self-citationIsotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
Guo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P., & Bhalla, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2629 · Cited by 202
Lindemann, R. K., Newbold, A., Whitecross, K. F., Cluse, L. A., Frew, A. J., Ellis, L., Williams, S., Wiegmans, A. P., Dear, A. E., Scott, C. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702294104 · Cited by 199
Self-citationWalczak, H., Bouchon, A., Stahl, H. F., & Krammer, P. H. (2000) · PubMed · Cited by 198
Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental Autoimmune Encephalomyelitis
Hilliard, B., Wilmen, A., Seidel, C., Liu, T.-S. T., Göke, R., & Chen, Y. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.1314 · Cited by 198
Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2889 · Cited by 197
Wen, J., Ramadevi, N., Nguyen, D., Perkins, C., Worthington, E., & Bhalla, K. (2000) · Blood · doi:10.1182/blood.v96.12.3900 · Cited by 196
Association of a Common Variant of the CASP8 Gene With Reduced Risk of Breast Cancer
MacPherson, G., Healey, C. S., Teare, M. D., Balasubramanian, S. P., Reed, M. W. R., Pharoah, P. D. P., Ponder, B. A. J., Meuth, M., Bhattacharyya, N. P., & Cox, A. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji001 · Cited by 196
The promise of TRAIL—potential and risks of a novel anticancer therapy
Koschny, R., Walczak, H., & Ganten, T. M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0194-1 · Cited by 195
Grosse-Wilde, A., Voloshanenko, O., Bailey, S. L., Longton, G. M., Schaefer, U., Csernok, A. I., Schütz, G., Greiner, E. F., Kemp, C. J., & Walczak, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33061 · Cited by 190
Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Safa, A., Day, T., & Wu, C.-H. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497087 · Cited by 184
Chen, X., Kandasamy, K., & Srivastava, R. K. (2003) · PubMed · Cited by 183
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis
Finnberg, N., Klein-Szanto, A. J. P., & El-Deiry, W. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci29900 · Cited by 180
Assessing Individual Risk for Prostate Cancer
Nam, R. K., Toi, A., Klotz, L. H., Trachtenberg, J., Jewett, M. A. S., Appu, S., Loblaw, D. A., Sugar, L., Narod, S. A., & Kattan, M. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6450 · Cited by 176
Critical roles of TRAIL in hepatic cell death and hepatic inflammation
Zheng, S.-J., Wang, P., Tsabary, G., & Chen, Y. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19255 · Cited by 173
Expression of TRAIL and TRAIL receptors in normal and malignant tissues
DANIELS, R. A., TURLEY, H., KIMBERLEY, F. C., LIU, X. S., MONGKOLSAPAYA, J., CH'EN, P., XU, X. N., JIN, B., PEZZELLA, F., & SCREATON, G. R. (2005) · Cell Research · doi:10.1038/sj.cr.7290311 · Cited by 173
Morel, J., Audo, R., Hahne, M., & Combe, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414469200 · Cited by 172
Martelli, A. M., Tazzari, P. L., Tabellini, G., Bortul, R., Billi, A. M., Manzoli, L., Ruggeri, A., Conte, R., & Cocco, L. (2003) · Leukemia · doi:10.1038/sj.leu.2403044 · Cited by 172
Ganten, T. M., Koschny, R., Haas, T. L., Sykora, J., Li-Weber, M., Herzer, K., & Walczak, H. (2005) · Hepatology · doi:10.1002/hep.20807 · Cited by 170
van der Sloot, A. M., Tur, V., Szegezdi, E., Mullally, M. M., Cool, R. H., Samali, A., Serrano, L., & Quax, W. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510187103 · Cited by 169
Greco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168
Zhang, X. D., Borrow, J. M., Zhang, X. Y., Nguyen, T., & Hersey, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206427 · Cited by 163
T cells require TRAIL for optimal graft-versus-tumor activity
Schmaltz, C., Alpdogan, O., Kappel, B. J., Muriglan, S. J., Rotolo, J. A., Ongchin, J., Willis, L. M., Greenberg, A. S., Eng, J. M., Crawford, J. M., et al. (2002) · Nature Medicine · doi:10.1038/nm1202-797 · Cited by 163
TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies
MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J. S., & Cohen, G. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2801 · Cited by 163
Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma
Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S., Kim, S. Y., Lee, J. H., Han, S. Y., Park, J. Y., Oh, R. R., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204103 · Cited by 162
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00113-8 · Cited by 161
Bockbrader, K., Tan, M., & Sun, Y. N. (2005) · Oncogene · doi:10.1038/sj.onc.1208888 · Cited by 161
Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S., Kim, S. Y., Lee, J. H., Han, S. Y., Park, J. Y., Oh, R. R., et al. (1999) · PubMed · Cited by 160
Song, J. H., Tse, M. C. L., Bellail, A., Phuphanich, S., Khuri, F., Kneteman, N. M., & Hao, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3896 · Cited by 160
Ohtsuka, T., Buchsbaum, D., Oliver, P., Makhija, S., Kimberly, R., & Zhou, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206290 · Cited by 159
Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies
Zerafa, N., Westwood, J. A., Cretney, E., Mitchell, S., Waring, P., Iezzi, M., & Smyth, M. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5586 · Cited by 159
Self-citationVolkmann, X., Fischer, U., Bahr, M. J., Ott, M., Lehner, F., MacFarlane, M., Cohen, G. M., Manns, M. P., Schulze‐Osthoff, K., & Bantel, H. (2007) · Hepatology · doi:10.1002/hep.21846 · Cited by 156
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N. W., Kennedy, D. B., Dyer, M. J. S., & Cohen, G. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401649 · Cited by 156
mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells
Panner, A., James, C. D., Berger, M. S., & Pieper, R. O. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.20.8809-8823.2005 · Cited by 156
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
Ishimura, N., Isomoto, H., Bronk, S. F., & Gores, G. J. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00242.2005 · Cited by 155
Frew, A. J., Lindemann, R. K., Martin, B. P., Clarke, C. J. P., Sharkey, J., Anthony, D. A., Banks, K.-M., Haynes, N. M., Gangatirkar, P., Stanley, K. L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801868105 · Cited by 155
Self-citationTo die or not to die—the quest of the TRAIL receptors
Degli‐Esposti, M. A. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.5.535 · Cited by 154
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802702105 · Cited by 148
Self-citationInvolvement of TRAIL and its receptors in viral hepatitis
Mundt, B., Kühnel, F., Zender, L., Paul, Y., Tillmann, H. L., Trautwein, C., Manns, M. P., & Kubicka, S. (2002) · The FASEB Journal · doi:10.1096/fj.02-0537fje · Cited by 143
Fisher, M. J., Virmani, A. K., Wu, L., Aplenc, R., Harper, J. C., Powell, S. M., Rebbeck, T. R., Sidransky, D., Gazdar, A. F., & El‐Deiry, W. S. (2001) · PubMed · Cited by 143
Deeb, D., Jiang, H., Gao, X., Hafner, M. S., Wong, H. K., Divine, G., Chapman, R., Dulchavsky, S. A., & Gautam, S. C. (2004) · PubMed · Cited by 141
Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition
Hallett, W. H. D., Ames, E., Motarjemi, M., Barão, I., Shanker, A., Tamang, D., Sayers, T. J., Hudig, D., & Murphy, W. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.163 · Cited by 139
Schneider, P., Olson, D. L., Tardivel, A., Browning, B., Lugovskoy, A. A., Gong, D., Dobles, M., Hertig, S., Hofmann, K., van Vlijmen, H., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210783200 · Cited by 136
Cancer immunotherapy: breaking the barriers to harvest the crop
Pardoll, D. M., & Allison, J. P. (2004) · Nature Medicine · doi:10.1038/nm0904-887 · Cited by 135
Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells
Khanbolooki, S., Nawrocki, S. T., Arumugam, T., Andtbacka, R. H. I., Pino, M. S., Kurzrock, R., Logsdon, C. D., Abbruzzese, J. L., & McConkey, D. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0075 · Cited by 132
Deeb, D., Jiang, H., Gao, X., Hafner, M. S., Wong, H., Divine, G., Chapman, R., Dulchavsky, S. A., & Gautam, S. C. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.803.3.7 · Cited by 131
Shankar, S., Chen, X., & Srivastava, R. K. (2004) · The Prostate · doi:10.1002/pros.20126 · Cited by 130
Who Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndromes?
Lynch, H. T., Boland, C. R., Rodríguez-Bigas, M. A., Amos, C. I., Lynch, J. F., & Lynch, P. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3119 · Cited by 124
Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL
Belka, C., Schmid, B., Marini, P., Durand, E., Rudner, J., Faltin, H., BAMBERG, M., Schulze‐Osthoff, K., & Budach, W. (2001) · Oncogene · doi:10.1038/sj.onc.1204318 · Cited by 124
Weckmann, M., Collison, A., Simpson, J. L., Kopp, M., Wark, P. A. B., Smyth, M. J., Yagita∥, H., Matthaei, K. I., Hansbro, N. G., Whitehead, B., et al. (2007) · Nature Medicine · doi:10.1038/nm1660 · Cited by 123
Self-citationCritical Roles of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand in Type 1 Diabetes
Lamhamedi-Cherradi, S.-E., Zheng, S. J., Tisch, R., & Chen, Y. H. (2003) · Diabetes · doi:10.2337/diabetes.52.9.2274 · Cited by 121
Herbst, R. S., Bajorin, D. F., Bleiberg, H., Blum, D., Hao, D., Johnson, B. E., Ozols, R. F., Demetri, G. D., Ganz, P. A., Kris, M. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8678 · Cited by 119
Bai, J., Sui, J., Demirjian, A. N., Vollmer, C. M., Marasco, W. A., & Callery, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3502 · Cited by 115
Methylation ofCASP8, DCR2, andHIN-1in Neuroblastoma Is Associated with Poor Outcome
Yang, Q., Kiernan, C. M., Tian, Y., Salwen, H. R., Chlenski, A., Brumback, B., London, W. B., & Cohn, S. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2846 · Cited by 113
Shankar, S., Singh, T. R., & Srivastava, R. K. (2004) · The Prostate · doi:10.1002/pros.20069 · Cited by 112
Rottmann, S., Wang, Y., Nasoff, M. S., Deveraux, Q. L., & Quon, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505114102 · Cited by 109
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells
Vogler, M., Dürr, K., Jovanovic, M., Debatin, K., & Fulda, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209776 · Cited by 109
Ray, S., & Almasan, A. (2003) · PubMed · Cited by 108
Daniel, D., Yang, B., Lawrence, D. A., Tótpál, K., Balter, I., Lee, W. P., Gogineni, A., Cole, M. J., Yee, S. F., Ross, S., et al. (2007) · Blood · doi:10.1182/blood-2007-02-076075 · Cited by 106
Failure of Bcl‐2 to block cytochrome c redistribution during TRAIL‐induced apoptosis
Keogh, S. A., Walczak, H., Bouchier‐Hayes, L., & Martin, S. J. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01375-2 · Cited by 106
Wang, X., Ju, W., Renouard, J. J., Aden, J. K., Belinsky, S. A., & Lin, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2698 · Cited by 106
Motoki, K., Mori, E., Matsumoto, A., Thomas, M., Tomura, T., Humphreys, R. C., Albert, V. R., Muto, M., Yoshida, H., Aoki, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1867 · Cited by 103
Zhang, X. D., Gillespie, S., Borrow, J. M., & Hersey, P. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00509-4 · Cited by 101
Avoiding premature apoptosis of normal epidermal cells
Qin, J., Chaturvedi, V., Bonish, B. K., & Nickoloff, B. J. (2001) · Nature Medicine · doi:10.1038/86401 · Cited by 100
Mundt, B., Wirth, T., Zender, L., Waltemathe, M., Trautwein, C., Manns, M. P., Kühnel, F., & Kubicka, S. (2005) · Gut · doi:10.1136/gut.2004.056929 · Cited by 100
Bremer, E., Samplonius, D. F., van Genne, L., Dijkstra, M. H., Kroesen, B. J., de Leij, L. F. M. H., & Helfrich, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413673200 · Cited by 98
Ng, C., & Bonavida, B. (2002) · PubMed · Cited by 98
Overexpression of FLIPL Is an Independent Marker of Poor Prognosis in Colorectal Cancer Patients
Ullenhag, G. J., Mukherjee, A., Watson, N. F., Al‐Attar, A., Scholefield, J. H., & Durrant, L. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2547 · Cited by 98
TNF‐related apoptosis‐inducing ligand as a therapeutic agent in autoimmunity and cancer
Cretney, E., Shanker, A., Yagita∥, H., Smyth, M. J., & Sayers, T. J. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01413.x · Cited by 97
Self-citationLeverkus, M., Walczak, H., McLellan, A. D., Fries, H.-W., Terbeck, G., Bröcker, E., & Kämpgen, E. (2000) · Blood · doi:10.1182/blood.v96.7.2628 · Cited by 95
Frese, S., Pirnia, F., Miescher, D., Krajewski, S., Borner, M., Reed, J. C., & Schmid, R. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206842 · Cited by 94
Bortul, R., Tazzari, P. L., Cappellini, A., Tabellini, G., Billi, A. M., Bareggi, R., Manzoli, L., Cocco, L., & Martelli, A. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402793 · Cited by 94
Herbst, R. S., Mendolson, D. S., Ebbinghaus, S., Gordon, M. S., O'Dwyer, P. J., Lieberman, G., Ing, J., Kurzrock, R., Novotny, W. F., & Eckhardt, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3013 · Cited by 94
TRAIL mediates liver injury by the innate immune system in the bile duct–ligated mouse†
Kahraman, A., Barreyro, F. J., Bronk, S. F., Werneburg, N. W., Mott, J. L., Akazawa, Y., Masuoka, H. C., Howe, C. L., & Gores, G. J. (2008) · Hepatology · doi:10.1002/hep.22136 · Cited by 92
Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies
Rudner, J., Jendrossek, V., Lauber, K., Daniel, P. T., Wesselborg, S., & Belka, C. (2004) · Oncogene · doi:10.1038/sj.onc.1208191 · Cited by 90
Higuchi, H., Bronk, S. F., Taniai, M., Canbay, A. E., & Gores, G. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.040030 · Cited by 88
Karikari, C. A., Roy, I., Tryggestad, E., Feldmann, G., Pinilla, C., Welsh, K., Reed, J. C., Armour, E. P., Wong, J. W., Herman, J. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0634 · Cited by 87
Roué, G., Pérez‐Galán, P., López‐Guerra, M., Villamor, N., Campo, E., & Colomer, D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1923 · Cited by 85
Shrader, M., Pino, M. S., Lashinger, L. M., Bar‐Eli, M., Adam, L., Dinney, C. P., & McConkey, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1224 · Cited by 85
Janssen, H. L. A., Higuchi, H., Abdulkarim, A., & Gores, G. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00265-4 · Cited by 84
Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2
Mori, E., Thomas, M., Motoki, K., Nakazawa, K., Tahara, T., Tomizuka, K., Ishida, I., & Kataoka, S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401331 · Cited by 84
Bin, L., Thorburn, J., Thomas, L. R., Clark, P. E., Humphreys, R. C., & Thorburn, A. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704210200 · Cited by 83
Baader, E., Toloczko, A., Fuchs, U., Schmid, I., Beltinger, C. P., Ehrhardt, H., Debatin, K., & Jeremias, I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4278 · Cited by 82
Wuchter, C., Krappmann, D., Cai, Z., Ruppert, V., Scheidereit, C., Dörken, B., Ludwig, W.-D., & Karawajew, L. (2001) · Leukemia · doi:10.1038/sj.leu.2402131 · Cited by 76
El-Zawahry, A. M., McKillop, J. C., & Voelkel‐Johnson, C. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-2 · Cited by 75
TRAIL limits excessive host immune responses in bacterial meningitis
Hoffmann, O. M., Priller, J., Prozorovski, T., Schulze‐Topphoff, U., Baeva, N., Lünemann, J. D., Aktaş, O., Mahrhofer, C., Stricker, S., Zipp, F., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30356 · Cited by 75
VanOosten, R. L., Moore, J. M., Ludwig, A. T., & Griffith, T. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.008 · Cited by 74
Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis
Secchiero, P., & Zauli, G. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f15fa6 · Cited by 73
PI‐3K/Akt and NF‐κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment
Zauli, G., Sancilio, S., Cataldi, A., Sabatini, N., Bosco, D., & Pietro, R. D. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20202 · Cited by 71
Sah, N. K., Munshi, A., Kurland, J. F., McDonnell, T. J., Su, B., & Meyn, R. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211010200 · Cited by 70
Maddipatla, S., Hernandez‐Ilizaliturri, F. J., Knight, J., & Czuczman, M. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0680 · Cited by 70
Belyanskaya, L. L., Marti, T. M., Hopkins-Donaldson, S., Kurtz, S., Felley‐Bosco, E., & Stahel, R. A. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-66 · Cited by 70
Sparano, J. A., Moulder, S. L., Kazi, A., Vahdat, L. T., Li, T., Pellegrino, C. M., Munster, P. N., Malafa, M. P., Lee, D., Hoschander, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9114 · Cited by 68
Yee, L., Fanale, M. A., Dimick, K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8078 · Cited by 68
Targeting the FLICE Inhibitory Protein (FLIP) in Cancer Therapy
Wajant, H. (2003) · Molecular Interventions · doi:10.1124/mi.3.3.124 · Cited by 67
Lagneaux, L., Gillet, N. A., Stamatopoulos, B., Delforge, A., Dejeneffe, M., Massy, M., Meuleman, N., Kentos, A., Martiat, P., Willems, L., et al. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.06.014 · Cited by 65
Rosato, R. R., Dai, Y., Almenara, J. A., Maggio, S. C., & Grant, S. (2004) · Leukemia · doi:10.1038/sj.leu.2403491 · Cited by 63
Zeng, Y., Wu, X., Fiscella, M., Shimada, O., Humphreys, R. C., Albert, V. R., & Kakehi, Y. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.2.421 · Cited by 63
Kim, K. M., Song, J. J., An, J. Y., Kwon, Y. T., & Lee, Y. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503713200 · Cited by 63
Horak, P., Pils, D., Kaider, A., Pinter, A., Elandt, K., Sax, C., Zielinski, C. C., Horvat, R., Zeillinger, R., Reinthaller, A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1276 · Cited by 63
Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms
Dumitru, C. A., Carpinteiro, A., Trarbach, T., Hengge, U. R., & Gulbins, E. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0081-9 · Cited by 62
Broaddus, V. C., Dansen, T. B., Abayasiriwardana, K. S., Wilson, S. M., Finch, A. J., Swigart, L. B., Hunt, A. E., & Evan, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408190200 · Cited by 58
Şanlioğlu, A. D., Korcum, A. F., Peştereli, E., Erdoğan, G., Karaveli, Ş., Savaş, B., Griffith, T. S., & Şanlıoğlu, S. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.03.057 · Cited by 56
Fas Signaling in Thyroid Carcinomas Is Diverted from Apoptosis to Proliferation
Mitsiades, C. S., Poulaki, V., Fanourakis, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2493 · Cited by 55
Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells
Siegmund, D., Klose, S., Zhou, D., Baumann, B., Röder, C., Kalthoff, H., Wajant, H., & Trauzold, A. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.12.008 · Cited by 53
On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils
Cassatella, M. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1005558 · Cited by 53
Yue, H., Diehl, G. E., & Winoto, A. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401523 · Cited by 51
LoRusso, P. M., Hong, D. S., Heath, E. I., Kurzrock, R., Wang, D., Hsu, M. L., Goyal, L., Wiezorek, J. S., Storgard, C. M., & Herbst, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3534 · Cited by 50
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Calvert, H., Plummer, E. R., Fox, N. L., Howard, T., Jones, S. F., & Burris, H. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14006 · Cited by 49
Wolf, S., Mertens, D., Pscherer, A., Schroeter, P., Winkler, D. F. H., Gröne, H., Hofele, C., Hemminki, K., Kumar, R., Steineck, G., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21502 · Cited by 47
Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer
Simons, M. P., Nauseef, W. M., & Griffith, T. S. (2007) · Immunologic Research · doi:10.1007/s12026-007-0084-1 · Cited by 44
Shamimi-Noori, S. M., Yeow, W.-S., Ziauddin, M. F., Xin, H., Tran, T.-V., Xie, J., Loehfelm, A., Patel, P., Yang, J., Schrump, D. S., et al. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701120 · Cited by 41
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Self-citationApoptosis and cancer: the genesis of a research field
Cotter, T. G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2663 · Cited by 758
Protein S-nitrosylation in health and disease: a current perspective
Foster, M. W., Hess, D. T., & Stamler, J. S. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.06.007 · Cited by 752
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 721
Metadata
- Authors
- Johnstone, R. W., Frew, A. J., & Smyth, M. J.
- Venue
- Nature Reviews Cancer
- Published
- 2008-10
- Volume
- 8
- Issue
- 10
- Pages
- 782-798
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1987506447
- Cited by
- 834
- References
- 215
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.